Drug intelligence / Profile preview

TEV-56287

Development stage: Unknown
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules

Overview

TEV-56287 is a **small molecule drug** developed by Teva for the treatment of Parkinson's disease and has also been referenced for multiple system atrophy. It acts as an **alpha-synuclein inhibitor**, a mechanism believed to target the misfolding and accumulation of alpha-synuclein protein implicated in Parkinsonian neurodegeneration. The compound is in preclinical to Phase 1 stages; detailed molecular targets, binding profiles, or comprehensive safety/efficacy profiles have not been fully disclosed. TEV-56287 may also be identified by the code name "sery433". Teva is noted as both developer and current active organization, with no regulatory approvals or recorded adverse events as of latest updates[1][5][9].

Other names: TEV-56287TEV56287TEV 56287sery433sery-433sery 433

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on TEV-56287.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEV-56287.

Explore the full profile